6. Visit Checklists

6.1	Overview of Section 6	6-1
6.2	Visit Checklists as Source Documentation	6-1
6.3	Use of the Checklists	6-1
6.4	Visit Checklist Templates	6-3

6.1 Overview of Section 6

This section provides a template checklist for each of the required study visits. The use of visit checklists is strongly recommended but is optional; sites may modify them as needed.

6.2 Visit Checklists as Source Documentation

Checklists are convenient tools, which may serve as source documentation if designed and completed appropriately. These checklists alone may not be sufficient for documenting all procedures but can be used to indicate that the procedure was completed and by whom. Additional information could be documented on the checklist comment sections and/or chart notes. It is up to each site to determine whether and how to use the visit checklists as source documentation.

It also should be noted that the visit checklists outlined below depict the visit schedule for a participant completing all protocol-specified study visits. In what is hoped to be a rare occurrence, there may be cases where a participant may have a modified study visit; in which case, any modifications to the procedures could be noted in in the comment section of the checklists.

6.3 Use of the Checklists

One checklist should be used for each participant. A common way that checklists are used is for the checklist to follow the participant through the visit, as activities are completed they are checked off the list. The checklists are designed so that there is one for each visit. Sites may modify order of procedures to maximize the efficiency of site-specific study operations, with the following exceptions/considerations:

- Informed consent must be obtained before any study procedures are performed.
- Once informed consent is obtained, the first procedure to be performed should be assignment of PTID.

- Enrollment must take place after final confirmation and verification of eligibility and collection of blood for plasma storage. If a participant is subsequently found to be ineligible, the plasma archive sample should be destroyed.
- The Patient Health Questionnaire-9 (PHQ-9) is only to be administered at Enrollment. The CASI is administered at Enrollment (Week 0), Week 4, all injection visits in Step 2, and all visits (except Week +8) in Step 3.
- During follow-up visits, behavioral assessment and acceptability assessments (CASI) should be administered prior to the delivery of HIV and adherence counseling.
- It is recommended that procedures for determining eligibility for continued product use be conducted early in the visit to ensure sufficient time is allowed for product to be available for administration.
- For visits where collection of blood for lipid profile is required, inquire early in the visit about last time the participant ate or drank. As a reminder, for lipid profile participants should have fasted for at least 8 hours (preferably 12 hours) prior to blood collection. Also, collect blood early in the visit so participants can have something to eat or drink immediately after blood collection.

When using the checklists, it is important that every item is completed - this is done by initialing and dating each step of the checklist (to show that the step was completed), or by entering ND (not done), or NA (not applicable) if a procedure is not performed. See checklist instructions for further information.

The source documentation for the procedure will need to be identified for some items that are in the protocol, but not on captured on the CRFs.

A good example of this is locator information. At each visit, the protocol requires that locator information is confirmed and, if necessary, updated. Some of the ways that the "act" of confirming or updating can be documented at each visit include writing a note in the participant's chart, creating a locator information log, or having a review/revision log attached to the locator information itself. The checklist cannot serve as the source for the confirmation of locator information unless it is revised to show who confirmed the information, if changes were made to the form.

6.4 Visit Checklist Templates

				Eligibility Checklist (Template)
	These a	re inclusion	ı criteria. 🛽	Any box checked "No" disqualifies the person from enrollment.
	Initials/ Date	Eligible	Not Eligible	
		Yes	No	Assigned female at birth
		Yes	No	At enrollment, aged below 18 years
		Yes	No	At enrollment, body weight \geq 35 kg (77 lbs.)
		Yes	No	Provided written informed assent/consent
		Yes	No	Self-reported sexual activity with a male (oral, anal or vaginal) in the past 12 months
Demographic/Medical/Behavioral		Yes	No	 In general, good health, as evidenced by the following laboratory values: Non-reactive / negative HIV test results Absolute neutrophil count > 799 cells/mm3, Platelet count ≥ 100,000/mm3, Hemoglobin ≥ 11g/dL, Calculated creatinine clearance ≥ 60 mL/minute using modified Schwartz equation, Alanine aminotransferase (ALT) < 2.0 times the upper limit of normal (ULN) and total bilirubin (Tbili) ≤ 2.5 x ULN, Hepatitis B virus (HBV) surface antigen (HBsAg) negative and accepts vaccination, HCV Antibody negative.
D		Yes	No	Willing to undergo all required study procedures
		Yes	No	Negative beta human chorionic gonadotropin (β HCG) pregnancy test (sensitivity of \leq 25 mIU/mL) performed (and results known) on the same day as Enrollment and before initiating study product
		Yes	No	Agrees to use a reliable form of long acting contraception, during the trial and for 48 weeks after stopping the long acting injectable, or 30 days after stopping oral study product, from the list below: • Intrauterine device (IUD) or intrauterine system (IUS) that meets <1% failure rate as stated in the product label • Hormone-based contraceptive that meets <1% failure rate when used consistently and correctly as stated in the product label (implants or injectables only; this excludes combined oral contraception).
		Yes	No	If receiving PrEP from a non-study source, agrees to discontinue oral PrEP and receive CAB LA injections instead

The	ese are excli	usion criter	ia. Any box checked "Yes" disqualifies the person from enrollment.
Initials	Not Eligible	Eligible	
	Yes	No	Co-enrollment in any other HIV interventional research study or other concurrent studies which may interfere with this study (as provided by self-report or other available documentation)
	Yes	No	Past or current participation in HIV vaccine trial with exception for participants who can provide documentation of receipt of placebo
	Yes	No	Exclusively had sex with biological females in lifetime
	Yes	No	In the last 6 months (at the time of screening): • active or planned use of any substance use which would, in the opinion of the site investigator, would hinder study participation (including herbal remedies), as described in the IB or listed in the SSP, and/ or Protocol Section 4.4,
_	Yes	No	Known history of clinically significant cardiovascular disease, as defined by history/evidence of symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease
_	Yes	No	Inflammatory skin conditions that compromise the safety of intramuscular (IM) injections
_	Yes	No	Tattoo or other dermatological condition overlying the buttock region that may interfere with interpretation of injection site reactions;
	Yes	No	Current or chronic history of liver disease (e.g., non-alcoholic or alcoholic steatohepatitis) or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome, asymptomatic gallstones, or cholecystectomy)
	Yes	No	Known history of clinically significant bleeding
	Yes	No	A history of seizure disorder, per self-report
	Yes	No	Medical, social, or other condition that, in the opinion of the site investigator, would interfere with the conduct of the study or the safety of the participant (e.g., provided by self-report, or found upon medical history and examination or in available medical records)
	Yes	No	Plans to move out of the geographic area within the next 18 months or otherwise unable to participate in study visits, according to the site investigator
	Yes	No	Pregnant or currently breastfeeding at the time of screening or intends to become pregnant and/or breastfeed while on study

The Investigator of Record or a Physician Sub-investigate	or listed on the Form FDA 1572, must review the					
eligibility checklist, as well as reports of information pertinent to the study, and sign and date the						
checklist to document his/her review and confirmation of	Eeligibility.					
Signature Line: Investigator of Record	Date					
or designated Physician Sub-investigator						

Participant ID		Visit Date						

		Screening Visit	
Initial/date	Completed	Procedure	Comments
		Confirm participant identity and age per site SOPs.	
		Determine screening attempt (Verify if HPTN 084-01 PTID has previously been assigned); see Protocol Section 5.1 First attempt ==> CONTINUE. Second attempt ==> Was CMC contacted? Attach communication to the checklist.	
		Obtain written assent/consent for screening/enrollment If the individual does not consent to screening, STOP screening procedures.	
		Assign Participant ID and record on the screening log	
		Demographic information may be collected at either Screening or Enrollment	
		Collect locator information per site SOP	
		Targeted medical history (including bleeding history and concomitant medications)	
		Contraception counselling and provision or verification of use	
		Perform targeted physical exam for ascertainment of eligibility	
		Provide HIV pre-test counseling	

Participant ID		Visit Date						

		Screening Visit	
Initial/date	Completed	Procedure	Comments
		Collect blood and perform testing for: HIV testing FDA-cleared HIV rapid test 4th or 5th generation HIV immunoassay HIV RNA performed within 14 days of Enrollment. NOTE: 14-day window starts on the day the sample for HIV RNA is collected, which is considered Day 0. Hepatitis testing: HBsAg, HBcAb and HCVAb CBC with differential Chemistry panel (creatinine only at Screening) Syphilis testing GC/CT testing (urine and/or vaginal swab) LFTs (ALT and bilirubin) Plasma for storage	
		Pregnancy testing	
		Provide HIV post-test counseling	
		Offer condoms and lubricant; document whether participant took them	
screening pro reason for ine	cedures. Info eligibility in th	ria listed above, the participant is not eligible, STOP rm the participant of his/her ineligibility. Document the he Screening Log. Retain documentation completed thus far, Outcomes CRF to the HPTN SDMC.	
		Schedule enrollment visit, if eligible thus far	
		Provide participant reimbursement and site contact information, if applicable	

Participant ID	Visit Date
INSTRUCTIONS: Enter staff initials next to each procedure completed If other staff members are not available to initial next to the procedure who completed the procedure. If all procedures listed on a checklist checklist, it is not necessary to enter the date beside each item. It dates, enter the date upon which each procedure is performed bes and all done on the same date is also acceptable. If a procedure lister or "NA" for "not applicable" beside the item and record the reason we	ure they completed, add a note on the checklist documenting t are performed on the date entered in the top section of the f procedures listed on a checklist are performed on multiple ide each item. Bracketing procedures which are consecutive ed on the checklist is not performed, enter "ND" for "not done"
NOTE: For a listing of forms required at each visit, otherwise refer to Section 13.13 of the Data Management Section of the	· ·
Additional information for Screening Visit: Please refe 084-01 Protocol.	r to Section 5.1 and Appendix I of the HPTN
Comments:	

Participant ID	Visit Date

		Step 1: Enrollment, Week 0/Day 0	
Initial/date	Completed	Procedures	Comments
		Confirm participant identity and PTID.	
		Confirm participant eligibility to continue with Enrollment visit based on Screening test results. Provide participant with test results.	
		Confirm last time participant ate. Reminder: Participants should have fasted for at least 8 hours (preferably 12 hours) prior to blood collection.	
		Verify participant is within the screening window. ☐ Within 30 days of specimen collection ☐ Within 14 days of HIV RNA sample collection	
		Administer PHQ-9.	
		Confirm HIV test results from screening visit (rapid HIV test, 4 th or 5 th generation immunoassay, HIV RNA) have been reviewed and are negative/non-reactive.	
		Confirm that informed consent was obtained and review elements of the consent as needed.	
		Review/update locator information.	
		Collect demographic information (if not collected at Screening).	
		Collect complete medical history including concomitant medications.	
		Perform full physical exam.	
		Complete Enrollment CASI.	

articipant I	D		Visit [Da	te				
f other staff men who completed shecklist, it is no lates, enter the and all done on to or "NA" for "not a NOTE: For a lis	mbers are not ava the procedure. If a ot necessary to er date upon which of the same date is a applicable" beside	next to each procedure completed. Do not initial procedurilable to initial next to the procedure they completed, adult procedures listed on a checklist are performed on the nter the date beside each item. If procedures listed on each procedure is performed beside each item. Bracket ilso acceptable. If a procedure listed on the checklist is not the item and record the reason why (if not self-explanate equired at each visit, otherwise known as the HPTN ata Management Section of this SSP.	d a note date en a checkling proceout performory); initi	or list edu me ial	the control that the co	hecklist the top erforme hich are er "ND" ate this	doo second o con for ' entr	tion of the control o	enting of the ultiple cutive done"
		Step 1: Enrollment, Week 0/Day 0							
Initial/date	Completed	Procedures				Co	mı	nen	ts
		Administer PHQ-9 eCRF							
		Collect vaginal swab(s).							
		Collect urine and perform testing for: Urinalysis (protein and glucose)							
vailable and Pesults from t	confirmed to b	rom Screening and at least one HIV test result e negative/non-reactive PRIOR to provision of esting, LFTs, lipid profile, hematology testing, product.	f study	p	roduc	et.			sit ar
		Provide HIV pre-test counseling							
		Collect blood and perform testing for: HIV testing FDA-cleared HIV rapid test 4th or 5th generation HIV immunoas Hepatitis B testing (HBsAb and HBcAHCVAb if not performed at Screening; must be available and discussed with performed to enrollment) CBC with differential Chemistry panel (BUN/Urea, creatining calcium, phosphorous, glucose, amylast LFTs (AST, ALT, total bilirubin, alkalit phosphatase) Fasting lipid profile (total cholesterol, Intriglycerides, LDL) Urinalysis (protein and glucose- can be locally or at the clinic)	e, CPK e, lipas ne	ant					

	Visit Dat	i e
bers are not ava e procedure. If a necessary to er ate upon which e e same date is a plicable" beside	ilable to initial next to the procedure they completed, add a note on all procedures listed on a checklist are performed on the date enterenter the date beside each item. If procedures listed on a checklist are performed beside each item. Bracketing procedures acceptable. If a procedure listed on the checklist is not performed the item and record the reason why (if not self-explanatory); initial and	the checklist documenting ed in the top section of the are performed on multiple res which are consecutive d, enter "ND" for "not done" and date this entry.
_		ledule of Forms, please
	Step 1: Enrollment, Week 0/Day 0	
Completed	Procedures	Comments
	Pregnancy Testing	
	Provide HIV post-test counseling	
	Provide adherence counseling	
	Contraception counselling and provision or verification of use	1
	Provide oral study drug and observe participant dose	
	Offer condoms and lubricant; document whether participant took products	
	Schedule next study visit. If possible, generate and review with participant the visit calendar for upcoming visits.	
	Provide site contact information and instructions to report symptoms and/or clarify any questions.	
	Remind participant to bring unused study product at next study visit.	
	pers are not ava e procedure. If a necessary to er ate upon which e e same date is a plicable" beside ing of forms red 13.13 of the Da	□ Pregnancy Testing □ Provide HIV post-test counseling □ Provide adherence counseling □ Contraception counselling and provision or verification of use □ Provide oral study drug and observe participant dose □ Offer condoms and lubricant; document whether participant took products □ Schedule next study visit. If possible, generate and review with participant the visit calendar for upcoming visits. □ Provide site contact information and instructions to

Participant ID	Visit Date			
Instructions: Enter staff initials next to each procedure completed. If other staff members are not available to initial next to the procedure who completed the procedure. If all procedures listed on a checklist a checklist, it is not necessary to enter the date beside each item. If plates, enter the date upon which each procedure is performed beside and all done on the same date is also acceptable. If a procedure listed or "NA" for "not applicable" beside the item and record the reason why	they completed, add a note on the checklist documenting re performed on the date entered in the top section of the cocedures listed on a checklist are performed on multiple each item. Bracketing procedures which are consecutive on the checklist is not performed, enter "ND" for "not done"			
NOTE: For a listing of forms required at each visit, otherwise known as the HPTN 084-01 Schedule of Forms, please refer to Section 13.13 of the Data Management Section of this SSP.				

Participant ID	Visit Date

Step 1: Weeks 2 and 4 (Oral Safety Visits) Circle applicable visit week				
Initials/date	Completed	Procedures	Comments	
		Confirm participant identity and PTID		
		Review/update locator information		
		Collect targeted medical history including concomitant medications		
		Week 4 only: Remind participants that the use of anticoagulant and/or antiplatelet medications as outlined are prohibited within 7 days before injections		
	П	Week 4 only: Participant completes Behavioral/Acceptability Assessment (CASI)		
		Perform targeted physical exam		
		Provide HIV pre-test counseling		
		Collect blood for: HIV testing FDA-cleared HIV rapid test 4th or 5th generation HIV immunoassay CBC with differential Chemistry panel (BUN/Urea, creatinine, CPK, calcium, phosphorous, glucose, amylase, lipase) LFTs (AST, ALT, total bilirubin, alkaline phosphatase) (Week 4 only) Plasma storage		
		Provide HIV post-test counseling		

Participant ID			Visit D	ate
If other staff memily who completed the checklist, it is not dates, enter the dates and all done on the	bers are not availa e procedure. If all necessary to ent ate upon which ea e same date is als	xt to each procedure completed. Do able to initial next to the procedure the procedures listed on a checklist are ear the date beside each item. If procedure is performed beside each procedure is performed beside each acceptable. If a procedure listed on the item and record the reason why (in	ney completed, add a note of performed on the date entegoedures listed on a checklist ach item. Bracketing process the checklist is not perform	on the checklist documenting ered in the top section of the st are performed on multiple dures which are consecutive ned, enter "ND" for "not done"
	•	uired at each visit, otherwise kno a Management Section of this SS		chedule of Forms, please
		Pregnancy testing		
		Contraception counselling a verification of use	and provision or	
		Urine and/or vaginal swab	collection	
		Hep B vaccination, if neede	ed (Week 2 only)	
		Conduct pill count (if the papills) and complete pill cou	nt follow-up CRF	
		If participant brought his pi today, observe dosing (com source)		e
		Provide adherence counseli	ng	
		Offer condoms and lubricar	ıt	
		Remind participant to bring at next study visit.	unused study product	
		Schedule next study visit		
		Provide site contact informate report symptoms and/or cla		0
		Provide participant reimbur	sement, if applicable	
Ü		se refer to Section 5.3 of the	HPTN 084-01 Protoco	ol

Participant ID)	Vis	it Date
If other staff mem who completed the checklist, it is not dates, enter the count and all done on the or "NA" for "not ap NOTE: For a list	bers are not available procedure. If a concessary to endate upon which ever same date is all oplicable" beside	lext to each procedure completed. Do not initial procedures lable to initial next to the procedure they completed, add a relative the date listed on a checklist are performed on the date of the date beside each item. If procedures listed on a checklist procedure is performed beside each item. Bracketing procedure is performed beside each item. Bracketing procedure is a procedure listed on the checklist is not performed the item and record the reason why (if not self-explanatory); a puired at each visit, otherwise known as the HPTN 084 at a Management Section of this SSP.	note on the checklist documenting a entered in the top section of the necklist are performed on multiple procedures which are consecutive rformed, enter "ND" for "not done" initial and date this entry.
		Step 2: Week 5 Visit (First Injection Visit)	
Initials/date	Completed	Procedures	Comments
		Confirm participant identity and PTID	
		Review/update locator information	
		Collect targeted medical history (including concomitant medications)	
		Perform targeted physical exam	
		Administer Step 2 Week 5 CASI	
		Provide HIV pre-test counseling	
		Collect blood and perform testing for: HIV testing FDA-cleared HIV rapid test 4th or 5th generation HIV immunoassay HIV Viral Load (detection limit <50 copies/mL) CBC with differential Chemistry Liver function Urinalysis (protein, glucose; at the clinic or	

NOTE BEFORE INJECTION: All HIV test results from previous visits and at least one HIV test result from the Week 5 visit must be available and confirmed to be negative/non-reactive PRIOR to injection of study product. The injection must not be given if any HIV test is reactive/positive.

Provide HIV post-test counseling

Plasma storage (must be drawn PRIOR to

injection)

Participant ID)	Visit D	Pate
If other staff mem who completed the checklist, it is not dates, enter the cand all done on the	bers are not ava ne procedure. If a necessary to en late upon which ne same date is a	next to each procedure completed. Do not initial procedures anotallable to initial next to the procedure they completed, add a note all procedures listed on a checklist are performed on the date enter the date beside each item. If procedures listed on a checkling procedure is performed beside each item. Bracketing procedure acceptable. If a procedure listed on the checklist is not perform the item and record the reason why (if not self-explanatory); initial	on the checklist documenting ered in the top section of the st are performed on multiple dures which are consecutive ned, enter "ND" for "not done"
	_	quired at each visit, otherwise known as the HPTN 084-01 S ata Management Section of this SSP.	Schedule of Forms, please
		ical and laboratory evaluations (e.g., chemistry, LFT y the IoR or their designee prior to injection.	s, hematology) must be
		Administer injection (with counseling about possible side effects and remind participants that the use of anticoagulant and/or antiplatelet medications are prohibited within 7 days after injections)	
		Provide adherence counseling	
		Urine collection	
		Pregnancy testing	
		Contraception counselling and provision or verification of use	
		Offer condoms and lubricant; document whether taken	
		Schedule next study visit	
		Provide site contact information and instructions to report symptoms and/or clarify any questions	
		Provide participant reimbursement, if applicable	
-		Fer to Section 5.5 of the HPTN 084-01 Protocol	

Participant ID	Visit Date

Participant ID	Visit Date

Step 2: (Safety Visits) Weeks 6, 10, 18, 26, 34 Circle applicable visit week			
Initials/date	Completed	Procedures	Comments
		Confirm participant identity and PTID	
		Review/update locator information	
		Collect targeted medical history (including concomitant medications)	
		Remind participants that the use of anticoagulant and/or antiplatelet medications are prohibited within 7 days before and after injections	
		Perform targeted physical exam	
		Conduct ISR evaluation	
		Provide HIV pre-test counseling	
		HIV testing □ FDA-cleared HIV rapid test □ Laboratory based, instrument HIV Immunoassay (HIV antigen and antibody) □ HIV Viral Load (detection limit <50 copies/mL)	
		Provide HIV post-test counseling	
		Collect blood for: CBC with differential Chemistry panel (BUN/Urea, creatinine, CPK, calcium, phosphorous, glucose,	

Participant ID		Visit Date	
INSTRUCTIONS: Enter staff initials next to each procedure completed. Do not initial procedures another staff member completed. If other staff members are not available to initial next to the procedure they completed, add a note on the checklist documenting who completed the procedure. If all procedures listed on a checklist are performed on the date entered in the top section of the checklist, it is not necessary to enter the date beside each item. If procedures listed on a checklist are performed on multiple dates, enter the date upon which each procedure is performed beside each item. Bracketing procedures which are consecutive and all done on the same date is also acceptable. If a procedure listed on the checklist is not performed, enter "ND" for "not done" or "NA" for "not applicable" beside the item and record the reason why (if not self-explanatory); initial and date this entry.			
•		red at each visit, otherwise known as the HPTN 084-01 Schedule of Forms, please Management Section of this SSP.	
		amylase, lipase) □ LFTs (AST, ALT, total bilirubin, alkaline phosphatase) □ Plasma storage	
		Collect urine for: Urinalysis (protein, glucose; at the clinic or local lab)	
		Hep B vaccination (if needed) – Weeks 6 and 33 only*	
		Provide adherence counseling	
		Offer condoms and lubricant; document whether taken	
		Provide site contact information and instructions to report symptoms and/or clarify any questions	
		Schedule next study visit	
		Provide TDF/FTC at Week 34 (3 months' worth)*	
		Qualitative interviews begin approximately at Week 34	
		Provide participant reimbursement, if applicable	
according to access to. (https://imm hepatitis-b-	to the production to the produ	VACCINATION, IF NEEDED: HBV vaccine schedules differ ct. Sites should create the schedule that fits the product they have formation, see: ndbook.health.gov.aw/resources/handbook-tables/table-monovalent-r-adolescents-and-adults.) Provision of TDF/FTC does not happen at Week 34 if the	
		remain on injections by transitioning to HPTN 084 OLE.	

Participant ID	Visit Date
INSTRUCTIONS: Enter staff initials next to each procedure complete If other staff members are not available to initial next to the procedure who completed the procedure. If all procedures listed on a checklichecklist, it is not necessary to enter the date beside each item. dates, enter the date upon which each procedure is performed be and all done on the same date is also acceptable. If a procedure list or "NA" for "not applicable" beside the item and record the reason	dure they completed, add a note on the checklist documenting ist are performed on the date entered in the top section of the If procedures listed on a checklist are performed on multiple side each item. Bracketing procedures which are consecutive ted on the checklist is not performed, enter "ND" for "not done"
NOTE: For a listing of forms required at each visit, otherwis refer to Section 13.13 of the Data Management Section of the	· ·
Notes for Safety Visits: Please refer to Section 5.6 of th	he HPTN 084-01 Protocol
Comments:	

Participant ID	Visit Date

	Step 2: (Remaining Injection Visits) Weeks 9, 17, 25, 33 Circle applicable visit week			
Initial/date	Completed	Procedures		
		Confirm participant identity and PTID		
		Review/update locator information		
		Collect targeted medical history (including concomitant medications)		
		Perform targeted physical exam		
		Administer CASI	1	
		 □ Urinalysis (protein, glucose; at the clinic or local lab) □ GC/CT testing (urine or vaginal swabs) (Weeks 17, 33 only) 		
		Provide HIV pre-test counseling		
		Collect blood for HIV testing FDA-cleared HIV rapid test 4th or 5th generation HIV immunoassay HIV Viral Load (detection limit <50 copies/mL) CBC with differential Chemistry panel (BUN/Urea, creatinine, CPK, calcium, phosphorous, glucose, amylase, lipase) LFTs (AST, ALT, total bilirubin, alkaline phosphatase) Syphilis testing (Week 33 only) Plasma storage (must be drawn PRIOR to injection)		

Participant	ID	Visit [Date
If other staff me who completed checklist, it is a dates, enter the and all done or	embers are not avail the procedure. It not necessary to e date upon which the same date is	s next to each procedure completed. Do not initial procedures and vailable to initial next to the procedure they completed, add a note of all procedures listed on a checklist are performed on the date enter the date beside each item. If procedures listed on a check heach procedure is performed beside each item. Bracketing procedure also acceptable. If a procedure listed on the checklist is not performed the item and record the reason why (if not self-explanatory); initial	on the checklist documenting tered in the top section of the list are performed on multiple edures which are consecutive med, enter "ND" for "not done"
	•	required at each visit, otherwise known as the HPTN 084-01 Data Management Section of this SSP.	Schedule of Forms, please
refer to occur	511 10.10 OF GIC 1	buta management deciden of this dor .	
	Ste	p 2: (Remaining Injection Visits) Weeks 9, 17, 25, 3 Circle applicable visit week	3
Initial/date	Completed	Procedures	
		Provide HIV post-test counseling	
from the curi	rent visit must	ION: All HIV test results from previous visits and at le be available and confirmed to be negative/non-reactiv n must not be given if any HIV test is reactive/positive.	
	the other labo uired prior to	oratory evaluations (e.g., chemistry, LFTs, hematology injection.) from the current visit
		us safety visit clinical and laboratory evaluations (e.g., able and be reviewed by the IoR or their designee prior	
		Administer injection (with counseling about possible side effects and reminder that the use of anticoagulant and/or antiplatelet medications are prohibited within 7 days before and after injections)	
		Provide adherence counseling	
		Contraception counselling and provision or verification of use	
		Pregnancy testing	
		Offer condoms and lubricant; document whether taken	
		Provide site contact information and instructions to report symptoms and/or clarify any questions	
		Sahadula navt study visit	

Notes for remaining injection visits: Please refer to Section 5.5 of the HPTN 084-01 Protocol

Provide participant reimbursement, if applicable

Participant ID	Visit Date
INSTRUCTIONS: Enter staff initials next to each procedure complete If other staff members are not available to initial next to the proced who completed the procedure. If all procedures listed on a checklist checklist, it is not necessary to enter the date beside each item. dates, enter the date upon which each procedure is performed besand all done on the same date is also acceptable. If a procedure list or "NA" for "not applicable" beside the item and record the reason was also acceptable.	ure they completed, add a note on the checklist documenting st are performed on the date entered in the top section of the lf procedures listed on a checklist are performed on multiple side each item. Bracketing procedures which are consecutive ted on the checklist is not performed, enter "ND" for "not done"
NOTE: For a listing of forms required at each visit, otherwise refer to Section 13.13 of the Data Management Section of the	the state of the s
Comments:	

Participant ID	Visit Date

Step 3: (Step 3: (Open-label daily oral TDF/FTC) Weeks +8, +12,+24, +36 and +48 (post-last injection) Circle applicable visit week				
Initial/date	Completed	Procedures	Comments		
		Confirm participant identity and PTID			
		Review/update locator information			
		Collect targeted medical history (including concomitant medications)			
		Perform targeted physical exam			
		Every visit except Week +8: CASI			
		Qualitative interviews continue (approximately Weeks +12 and +24)			
		Every visit except Week +8: Collect urine			
		Provide HIV pre-test counseling			

Participant ID	Visit Date

Step 3: (0	Step 3: (Open-label daily oral TDF/FTC) Weeks +8, +12,+24, +36 and +48 (post-last injection) Circle applicable visit week			
Initial/date	Completed	Procedures	Comments	
		 □ HIV testing □ FDA-cleared HIV rapid test □ Laboratory based, instrument HIV □ Immunoassay (HIV antigen and antibody) □ HIV Viral Load (detection limit <50 copies/mL) □ CBC with differential (except Week +8) □ Chemistry panel (BUN/Urea, creatinine, CPK, calcium, phosphorous, glucose, amylase, lipase (Weeks +24 and +48 only) □ LFTs (AST, ALT, total bilirubin, alkaline phosphatase (Weeks +24 and +48 only) □ Syphilis testing (Week +36) □ GC/CT testing (urine or vaginal swabs) – (except Week +8) □ Urinalysis (protein, glucose; at the clinic or local lab) (except Week +8) □ Plasma storage (ALL visits including Week +8) □ DBS storage (Weeks +12, +24 and +48 only) 		
		Provide HIV post-test counseling		
		Contraception counselling and provision or verification of use		
		Pregnancy testing		

	D	Visit Da	ate
f other staff men who completed to thecklist, it is no lates, enter the and all done on the or "NA" for "not a	mbers are not available procedure. If of necessary to educe upon which the same date is applicable" beside	next to each procedure completed. Do not initial procedures anoth allable to initial next to the procedure they completed, add a note of all procedures listed on a checklist are performed on the date enterenter the date beside each item. If procedures listed on a checklist each procedure is performed beside each item. Bracketing procedures also acceptable. If a procedure listed on the checklist is not performed the item and record the reason why (if not self-explanatory); initial equired at each visit, otherwise known as the HPTN 084-01 Section of this SSP.	n the checklist documenting red in the top section of the tare performed on multiple ures which are consecutived, enter "ND" for "not done and date this entry.
Step 3: (C	Open-label da	nily oral TDF/FTC) Weeks +8, +12,+24, +36 and +48 Circle applicable visit week	
Step 3: (C	Open-label da		(post-last injection) Comments
· `		Circle applicable visit week	
• `		Circle applicable visit week Procedures Provide oral Tenofovir/Emtricitabine (Weeks +12,	
· `		Procedures Provide oral Tenofovir/Emtricitabine (Weeks +12, +24, +36) Provide adherence counseling (All Weeks except	Comments
<u>-</u> `		Procedures Provide oral Tenofovir/Emtricitabine (Weeks +12, +24, +36) Provide adherence counseling (All Weeks except Week +8))	Comments
· `		Procedures Provide oral Tenofovir/Emtricitabine (Weeks +12, +24, +36) Provide adherence counseling (All Weeks except Week +8)) Offer condoms and lubricant; document whether taken Provide site contact information and instructions to	Comments

Participant ID	Visit Date

Procedures	for Enrolled	Participants who Seroconvert (See Protocol Section 5 HIV Confirmation Visit, Weeks +12, +24, +36, +48	.11 and Appendix IV)
		Circle applicable visit week	
Initial/date	Completed	Procedures	Comments
		Confirm participant identity and PTID	
		Review/update locator information	
		Collect targeted medical history (including concomitant medications)	
		Perform targeted physical exam	
		Provide HIV pre-test counseling (HIV confirmation visit only)	
		Collect blood for: ☐ HIV testing (HIV confirmation visit only) ☐ HIV resistance testing (HIV confirmation visit only) ☐ DBS storage (HIV confirmation visit only) ☐ CD4 cell count (HIV confirmation visit, Weeks +24, +48 only) ☐ HIV viral load testing (HIV confirmation visit, Weeks +24, +48 only) ☐ Chemistry (BUN/Urea, creatinine, CPK, calcium, phosphorous, glucose, amylase, lipase; Weeks +24, +48 only) ☐ LFTs (AST, ALT, total bilirubin, alkaline phosphatase; Weeks +24, +48 only) ☐ Plasma storage (all visits)	
		Provide HIV post-test counseling (HIV confirmation visit only)	

articipant I	D	Visit Dat	е
f other staff men who completed whecklist, it is no lates, enter the and all done on	mbers are not ave the procedure. If ot necessary to e date upon which the same date is	next to each procedure completed. Do not initial procedures another ailable to initial next to the procedure they completed, add a note on all procedures listed on a checklist are performed on the date entered enter the date beside each item. If procedures listed on a checklist are each procedure is performed beside each item. Bracketing procedure also acceptable. If a procedure listed on the checklist is not performed be the item and record the reason why (if not self-explanatory); initial a	the checklist documenting of in the top section of the are performed on multiple res which are consecutively enter "ND" for "not done in the consecutive
	•	equired at each visit, otherwise known as the HPTN 084-01 Sch	nedule of Forms, pleas
ter to Section	П 13.13 OT the L	Pata Management Section of this SSP.	
Procedures	for Enrolled	Participants who Seroconvert (See Protocol Section 5: HIV Confirmation Visit, Weeks +12, +24, +36, +48	.11 and Appendix I
		Circle applicable visit week	
nitial/date	Completed	Procedures	Comments
		Offer condoms and lubricant; document whether taken	
		Provide site contact information and instructions to report symptoms and/or clarify any questions	
		Schedule next study visit, if applicable	
		Provide participant reimbursement, if applicable	

Participant ID	Visit Date